- Record: found
- Abstract: not found
- Article: not found
The antibody-drug conjugate (ADC) loncastuximab tesirine (ADCT-402) targeting CD19 shows strong in vitro anti-lymphoma activity both as single agents and in combination
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.